Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis.

Abstract	In sarcoidosis, chronic pulmonary aspergillosis (CPA) may be associated with significant morbidity, and treatment failure rates are often high, even with newer triazole antifungal agents. We report a treatment regimen of cyclical caspofungin infusions in 10 patients with sarcoidosis and worsening CPA despite oral triazoles.
Authors	Gregory J Keir, Benjamin Garfield, David M Hansell, Michael R Loebinger, Robert Wilson, Elisabetta A Renzoni, Athol U Wells, Toby M Maher
Journal	Thorax (Thorax) Vol. 69 Issue 3 Pg. 287-8 (Mar 2014) ISSN: 1468-3296 [Electronic] England
PMID	24029745 (Publication Type: Journal Article)
Chemical References	Antifungal Agents Echinocandins Lipopeptides Caspofungin
Topics	Adult Antifungal Agents (administration & dosage, therapeutic use) Caspofungin Chronic Disease Echinocandins (administration & dosage, therapeutic use) Female Follow-Up Studies Humans Immunocompromised Host Infusion Pumps Lipopeptides Male Middle Aged Pulmonary Aspergillosis (complications, diagnosis, drug therapy, mortality) Sarcoidosis (complications, diagnosis, drug therapy, mortality) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!